ATB-T2DM patients had elevated frequencies of central memory CD4+ and CD8+ T cells and decreased frequencies of naïve, effector memory, and/or effector CD4+ and CD8+ T cells at baseline and after two months of treatment, but not after six months of treatment in comparison to ATB-T2DM patients (88). This evidence concerns the gene CD8A and type 2 diabetes mellitus.